Hormonal
Subcutaneous semaglutide 2.4 mg administered once weekly reduces the risk of death from cardiovascular causes by 20% in patients with overweight or obesity without diabetes, based on the SELECT trial.
If you have had a heart attack and are overweight or obese but do not have diabetes, ask your doctor about semaglutide 2.4 mg. It is taken once weekly and has been shown to significantly reduce the risk of dying from heart-related causes. Be aware of potential stomach issues and the high cost if not covered by insurance.
The recent Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity (SELECT) trial demonstrated that subcutaneous semaglutide 2.4 mg administered once weekly in patients with overweight and obesity without diabetes reduces the risk of death from CV causes by 20% compared with placebo after a mean follow-up of 33 months [4].
Why this rating
Based on the SELECT trial, a large, randomized, placebo-controlled trial.
Source
Eligibility for Semaglutide 2.4 mg in Patients With Acute Myocardial Infarction and Overweight or Obesity Without Diabetes: A Real-World Analysis
R Ajmera et al. · Heart Lung and Circulation · 2025
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →